scholarly journals Long-Term Efficacy of S-1 Chemotherapy plus Administration of Octreotide for a Patient with Metastatic Neuroendocrine Tumor (Gastrinoma)

2017 ◽  
Vol 10 (2) ◽  
pp. 420-427 ◽  
Author(s):  
Sakura Hiraide ◽  
Sadahide Ono ◽  
Satoshi Kato
Keyword(s):  
Neuroendocrine Tumor ◽  
Poor Prognosis ◽  
Pancreatic Tumor ◽  
Liver Tumors ◽  
Pancreatic Neuroendocrine Tumor ◽  
Serious Adverse Event ◽  
Metastatic Neuroendocrine Tumor ◽  
Marked Suppression ◽  
Slow Tumor Growth

Metastatic neuroendocrine tumors (gastrinomas) have a poor prognosis. Octreotide can reduce gastrin levels and alleviate hormonal symptoms, and possibly slow tumor growth as well. No drugs were available except streptozocin for the treatment of metastatic pancreatic neuroendocrine tumor (PNET) in 2008. We report a case of PNET in a 53-year-old woman with multiple liver tumors treated with S-1 plus octreotide. After 6 months from the initiation of the treatment, the pancreatic tumor and liver metastases regressed, and the patient achieved partial response without the development of any serious adverse event. For more than 8 years, the patient has remained asymptomatic without disease progression and is continuing treatment with octreotide and S-1. A marked suppression of gastrin levels has also been achieved. Combination therapy with octreotide and S-1 has been effective and well tolerated in patients with metastatic gastrinoma.

scholarly journals Case Report: Grade 2 Metastatic Pancreatic Neuroendocrine Tumor With Progression of One Metastasis After Pregnancy to Grade 3 Large-Cell Neuroendocrine Carcinoma: One Case Cured by Resection With Genomic Characterization of the Two Components

2021 ◽  
Vol 11 ◽  
Author(s):  
Jean-Luc Raoul ◽  
Marie-Françoise Heymann ◽  
Frédéric Dumont ◽  
Alain Morel ◽  
Hélène Senellart ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Large Cell ◽  
Genomic Signatures ◽  
Pancreatic Net ◽  
Genomic Characterization ◽  
Poorly Differentiated ◽  
Grade 3

Temporal and spatial tumor heterogeneity can be observed in pancreatic neuroendocrine tumor. We report the case of a young woman with long term stabilization of a G2 metastatic pancreatic NET that, after pregnancy, suddenly progressed into one single liver metastasis corresponding to a transformation into G3 large-cell neuroendocrine cancer. The patient underwent liver resection (the progressive and one dormant metastasis). With a 45 months follow-up the patient is without evolutive disease. Exome sequencing of the two metastases revealed completely different genomic signatures and gene alterations: the dormant metastasis was MSS without any gene alteration; the poorly differentiated tumor was MSI, with gain of many mutations including MEN1, BCL2, MLH1 and TP53 corresponding to a mutational signature 11. Could temozolomide play a role in this transformation?

scholarly journals High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor

Medicine ◽  
2015 ◽  
Vol 94 (50) ◽  
pp. e2224 ◽  
Author(s):  
Yoon Suk Lee ◽  
Haeryoung Kim ◽  
Hyoung Woo Kim ◽  
Jong-Chan Lee ◽  
Kyu-Hyun Paik ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Poor Prognosis ◽  
Pancreatic Neuroendocrine Tumor ◽  
High Expression

scholarly journals CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Rami Imam ◽  
Qing Chang ◽  
Margaret Black ◽  
Caroline Yu ◽  
Wenqing Cao
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Neuroendocrine Tumor ◽  
Poor Prognosis ◽  
Lymphovascular Invasion ◽  
Perineural Invasion ◽  
Pancreatic Neuroendocrine Tumor ◽  
Node Metastasis ◽  
Well Differentiated ◽  
Lower Expression

Abstract Background Recent studies have suggested the important roles of CD47 and tumor-associated macrophages in the prognosis and immunotherapy of various human malignancies. However, the clinical significance of CD47 expression and CD163+ TAMs in pancreatic neuroendocrine tumor (PanNET) remains unclear. Methods In this study, 47 well-differentiated PanNET resection specimens were collected. CD47 expression and CD163+ macrophages were evaluated using immunohistochemistry and correlated with clinicopathologic properties. Results Positive CD47 staining was seen in all PanNETs as well as adjacent normal islets. Compared to normal islets, CD47 overexpressed in PanNETs (p = 0.0015). In the cohort, lymph node metastasis (LNM), lymphovascular invasion (LVI), and perineural invasion (PNI) were found in 36.2, 59.6, and 48.9% of the cases, respectively. Interestingly, PanNETs with LNM, LVI, or PNI had significantly lower H-score of CD47 than those without LNM (p = 0.035), LVI (p = 0.0005), or PNI (p = 0.0035). PanNETs in patients with disease progression (recurrence/death) also showed a significantly lower expression of CD47 than those without progression (p = 0.022). In contrast, CD163+ macrophage counts were significantly higher in cases with LNM, LVI, and PNI. Conclusions Our data suggest relative low CD47 expression and high CD163+ TAMs may act as indicators for poor prognosis of PanNETs.

Sign in / Sign up

Export Citation Format

Share Document